Cylene Pharmaceuticals   Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (2001)
Status: Defunct (2011)

Organization Overview

First Clinical Trial
2005
NCT00955786
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

quarfloxin (4 trials)

Drugs in Phase 1 Trials (1)

silmitasertib (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoid Tumor (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Castleman Disease (Phase 1)

Inflammatory Breast Neoplasms (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Neuroendocrine Tumors (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 2